Patents by Inventor David L. Gerhold

David L. Gerhold has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090298073
    Abstract: Novel biomarkers for kidney toxicity. Said biomarkers may be useful for optimization of lead compounds, or in safety assessment.
    Type: Application
    Filed: June 28, 2007
    Publication date: December 3, 2009
    Inventors: David L. Gerhold, Daniel J. Holder, Hong Jin, David J. Figueroa, Wendy J. Bailey, Josef S. Ozer, Ming Su
  • Patent number: 6030788
    Abstract: An isolated nucleic acid molecule is disclosed which encodes a novel human cyclin-dependent kinase (CDK) which comprises a novel cyclin binding domain signature sequence and lacks several heretofore conserved amino acid residues involved in regulation of the cdk/cyclin complex. Associated proteins and biologically active mutant forms are also disclosed.
    Type: Grant
    Filed: February 10, 1999
    Date of Patent: February 29, 2000
    Assignee: Merck & Co., Inc.
    Inventor: David L. Gerhold
  • Patent number: 5968800
    Abstract: An isolated nucleic acid molecule is disclosed which encodes a novel human cyclin-dependent kinase (CDK) which comprises a novel cyclin binding domain signature sequence and lacks several heretofore conserved amino acid residues involved in regulation of the cdk/cyclin complex. Associated proteins and biologically active mutant forms are also disclosed.
    Type: Grant
    Filed: February 5, 1998
    Date of Patent: October 19, 1999
    Assignee: Merck & Co., Inc.
    Inventor: David L. Gerhold
  • Patent number: 5942386
    Abstract: Substantially pure C. albicans topoisomerase I protein is disclosed. Nucleic acid molecules that encode C. albicans topoisomerase I protein, recombinant expression vectors that comprise a nucleic acid sequence that encodes C. albicans topoisomerase I protein, and host cells that comprise recombinant expression vectors that comprise nucleic acid sequences that encode C. albicans topoisomerase I protein are disclosed. Fragments of nucleic acid molecules with sequences encoding C. albicans topoisomerase I protein and oligonucleotide molecules that comprise a nucleotide sequence complementary to fragment of a nucleotide sequence that encodes C. albicans topoisomerase I protein are disclosed. Antibodies which bind to an epitope on C. albicans topoisomerase I protein are disclosed. Methods of identifying inhibitors of C. albicans topoisomerase I protein are disclosed. Camptothecin analogs useful as inhibitors of C.
    Type: Grant
    Filed: March 23, 1998
    Date of Patent: August 24, 1999
    Assignee: Thomas Jefferson University
    Inventors: Eric B. Kmiec, David L. Gerhold, Allyson Cole Strauss
  • Patent number: 5691187
    Abstract: Substantially pure C. albicans topoisomerase I protein is disclosed. Nucleic acid molecules that encode C. albicans topoisomerase I protein, recombinant expression vectors that comprise a nucleic acid sequence that encodes C. albicans topoisomerase I protein, and host cells that comprise recombinant expression vectors that comprise nucleic acid sequences that encode C. albicans topoisomerase I protein are disclosed. Fragments of nucleic acid molecules with sequences encoding C. albicans topoisomerase I protein and oligonucleotide molecules that comprise a nucleotide sequence complimentary to fragment of a nucleotide sequence that encodes C. albicans topoisomerase I protein are disclosed. Antibodies which bind to an epitope on C. albicans topoisomerase I protein are disclosed. Methods of identifying inhibitors of C. albicans topoisomerase I protein are disclosed.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 25, 1997
    Assignee: Thomas Jefferson University
    Inventors: Eric B. Kmiec, David L. Gerhold, Allyson Cole Strauss